Login
Companies $EOLS
$6.63 +$0.00 (0.0%) After hours
Evolus, Inc. logo

Evolus, Inc.

evolus.com

What Do They Do?

Sells injectable neurotoxins and hyaluronic acid gels, including Jeuveau and Evolysse, to licensed aesthetic practitioners.

How Do They Make Money?

Evolus sells Jeuveau and Evolysse to customers; product sales are tied to customers receiving the goods. In Canada, Jeuveau sales through a distribution partner generate service revenue as the service is performed.

revenue
SegmentShareRevenue
Product revenue, net
Sold outright

99%
FY2022: 99%
Service revenue
0.8%
FY2022: 1.4%

Who Are Their Customers?

Licensed aesthetic practitioners are its customers; Evolus uses a digital platform to open accounts and tailor purchasing, while Jeuveau sales in Canada go through a distribution partner.

Do Revenues Turn Into Profits?

No. It lost $51.6M in FY2025.

Operating income, FY2025
−11% of revenue
▲ +5% (Loss) vs FY2024 (−$34.4M, −13%)
Net income, FY2025
−17% of revenue
▼ −2% (Loss) vs FY2024 (−$50.4M, −19%)
Free cash flow, FY2025
−15% of revenue
▼ −135% (Loss) vs FY2024 (−$19.5M, −7%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
▲ +13%
vs $69M in Q3 FY2025
Net income
▲ +20% (Loss)
vs −$15.7M in Q3 FY2025
Product revenue, net share of revenue vs 100.0% in Q3 FY2025
  • Aug 5, 2026 Raised its full-year revenue guidance The same announcement adds Profhilo to its U.S. injectable portfolio and reports broader Estyme licensing.
  • Aug 4, 2026 Expanded Estyme rights into additional markets The exclusive license covers Canada, Australia, and New Zealand, with commercialization subject to regulatory approvals.
  • Jul 8, 2026 Licensed Profhilo rights for U.S. development and sales Evolus will handle U.S. development and regulatory activities and, after approval, purchase the product from IBSA.

Growing. Revenue grew 3.0x in 4 years, from $99.7M in FY2021 to $297.2M in FY2025, about 31% a year.

Added injectable HA gels The older report described Jeuveau as its first commercial product; the latest report also includes Evolysse injectable HA gels, with products launched in the United States.

Revenue over time
Product revenue, net Service revenue
$500M$250M$0

Who Do They Compete With?

Competes with Abbvie, Galderma, Merz, Revance, Hugel, Medytox, Prollenium Medical Technologies, Obagi, Sanofi, Sun Pharma, Johnson & Johnson, and L’Oreal

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support